Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Equivalents (2020 - 2023)

Historic Cash & Equivalents for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $37.9 million.

  • Terns Pharmaceuticals' Cash & Equivalents fell 3983.04% to $37.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $37.9 million, marking a year-over-year decrease of 3983.04%. This contributed to the annual value of $143.2 million for FY2022, which is 20028.93% up from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Cash & Equivalents of $37.9 million as of Q3 2023, which was down 3983.04% from $80.9 million recorded in Q2 2023.
  • Terns Pharmaceuticals' Cash & Equivalents' 5-year high stood at $184.4 million during Q1 2023, with a 5-year trough of $11.7 million in Q1 2020.
  • In the last 4 years, Terns Pharmaceuticals' Cash & Equivalents had a median value of $63.0 million in 2022 and averaged $64.6 million.
  • As far as peak fluctuations go, Terns Pharmaceuticals' Cash & Equivalents surged by 74498.12% in 2021, and later plummeted by 7513.5% in 2022.
  • Over the past 4 years, Terns Pharmaceuticals' Cash & Equivalents (Quarter) stood at $74.9 million in 2020, then crashed by 36.28% to $47.7 million in 2021, then soared by 200.29% to $143.2 million in 2022, then tumbled by 73.54% to $37.9 million in 2023.
  • Its Cash & Equivalents was $37.9 million in Q3 2023, compared to $80.9 million in Q2 2023 and $184.4 million in Q1 2023.